Dynavax Technologies Corp (NASDAQ:DVAX) Institutional Investors Sentiment Index Improved in 2018 Q1

June 16, 2018 - By Migdalia James

Dynavax Technologies Corporation (NASDAQ:DVAX) Logo

Sentiment for Dynavax Technologies Corp (NASDAQ:DVAX)

Dynavax Technologies Corp (NASDAQ:DVAX) institutional sentiment increased to 1.21 in Q1 2018. Its up 0.21, from 1 in 2017Q4. The ratio has improved, as 63 investment professionals increased or started new positions, while 52 cut down and sold their stock positions in Dynavax Technologies Corp. The investment professionals in our partner’s database now possess: 46.77 million shares, up from 43.53 million shares in 2017Q4. Also, the number of investment professionals holding Dynavax Technologies Corp in their top 10 positions was flat from 0 to 0 for the same number . Sold All: 19 Reduced: 33 Increased: 37 New Position: 26.

Dynavax Technologies Corporation, a clinical-stage immunotherapy company, focuses on leveraging the power of the bodyÂ’s innate and adaptive immune responses through toll-like receptor stimulation. The company has market cap of $1.01 billion. The Company’s product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. It currently has negative earnings. The companyÂ’s lead product candidates include HEPLISAV-B, an investigational adult hepatitis B vaccine, which is in Phase III clinical trials; and SD-101, an investigational cancer immunotherapeutic that is in Phase I/II studies.

The stock increased 1.57% or $0.25 during the last trading session, reaching $16.15. About 889,711 shares traded. Dynavax Technologies Corporation (NASDAQ:DVAX) has risen 201.80% since June 16, 2017 and is uptrending. It has outperformed by 189.23% the S&P500.

Analysts await Dynavax Technologies Corporation (NASDAQ:DVAX) to report earnings on August, 1. They expect $-0.58 EPS, down 41.46 % or $0.17 from last year’s $-0.41 per share. After $-0.63 actual EPS reported by Dynavax Technologies Corporation for the previous quarter, Wall Street now forecasts -7.94 % EPS growth.

Consonance Capital Management Lp holds 3.01% of its portfolio in Dynavax Technologies Corporation for 1.66 million shares. First Light Asset Management Llc owns 453,634 shares or 1.98% of their US portfolio. Moreover, Venbio Select Advisor Llc has 1.56% invested in the company for 1.65 million shares. The Georgia-based Gmt Capital Corp has invested 1.06% in the stock. Northpointe Capital Llc, a Michigan-based fund reported 386,955 shares.

Since January 1, 0001, it had 0 insider purchases, and 5 selling transactions for $985,431 activity.

Dynavax Technologies Corporation (NASDAQ:DVAX) Ratings Coverage

Ratings analysis reveals 80% of Dynavax’s analysts are positive. Out of 5 Wall Street analysts rating Dynavax, 4 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $2500 while the high is $3000. The stock’s average target of $26.40 is 63.47% above today’s ($16.15) share price. DVAX was included in 12 notes of analysts from January 22, 2018. The stock of Dynavax Technologies Corporation (NASDAQ:DVAX) has “Hold” rating given on Wednesday, February 14 by J.P. Morgan. JP Morgan downgraded the shares of DVAX in report on Wednesday, February 14 to “Neutral” rating. The company was maintained on Tuesday, April 17 by Cowen & Co. Cantor Fitzgerald maintained the stock with “Buy” rating in Tuesday, May 8 report. The rating was maintained by Cantor Fitzgerald on Thursday, March 8 with “Buy”. Cantor Fitzgerald maintained it with “Buy” rating and $2700 target in Monday, April 16 report. The firm has “Buy” rating by RBC Capital Markets given on Monday, January 22. As per Thursday, March 8, the company rating was maintained by RBC Capital Markets. Cantor Fitzgerald maintained it with “Buy” rating and $2700 target in Monday, June 4 report. The rating was upgraded by JP Morgan to “Overweight” on Thursday, May 10.

More notable recent Dynavax Technologies Corporation (NASDAQ:DVAX) news were published by: Seekingalpha.com which released: “Dynavax Gives A Welcome Business Update” on June 16, 2018, also Nasdaq.com with their article: “Dynavax to Present at the William Blair 38th Annual Growth Stock Conference” published on June 06, 2018, Investorplace.com published: “7 Strong Buy Stocks Analysts Are Upgrading Now, Including Facebook, Inc.” on June 13, 2018. More interesting news about Dynavax Technologies Corporation (NASDAQ:DVAX) were released by: Seekingalpha.com and their article: “The Market Completely Misunderstood The Dynavax SD-101 Data” published on May 22, 2018 as well as Globenewswire.com‘s news article titled: “Dynavax Reports Data for Phase 1b/2 Trial of SD-101 in Combination with KEYTRUDA® (pembrolizumab) in …” with publication date: June 04, 2018.

Dynavax Technologies Corporation (NASDAQ:DVAX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: